-

Fujifilm Completes Acquisition of Shenandoah Biotechnology

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, completed the acquisition of Shenandoah Biotechnology, Inc., a leading manufacturer of recombinant proteins. Terms of the deal were not disclosed.

Located in Warminster, Pennsylvania, Shenandoah Biotechnology manufactures recombinant proteins including cytokines and growth factors. Shenandoah Biotechnology recently launched their CTG Grade™ line of cytokines and growth factors that are manufactured according to cGMP guidelines in the Company’s new state-of-the-art, ISO 9001:2015 certified facility.

Shenandoah Biotechnology’s portfolio of recombinant proteins complements FUJIFILM Irvine Scientific, Inc.’s advanced cell culture solutions and expertise in bioprocessing, which will provide customers with a single point of access for their life science research, discovery, and cell and gene therapy needs.

Contacts

Lily Jeffery
Zyme Communications
Phone: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com

Irvine Scientific


Release Versions

Contacts

Lily Jeffery
Zyme Communications
Phone: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com

More News From Irvine Scientific

FUJIFILM Irvine Scientific Now Officially FUJIFILM Biosciences

SANTA ANA, Calif.--(BUSINESS WIRE)--FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, today announced the Company has officially changed its legal name from FUJIFILM Irvine Scientific, Inc., to FUJIFILM Biosciences Inc., effective January 1, 2026. The FUJIFILM Biosciences’ name builds upon the Company’s roots as a pioneer in the cell culture media industry that through a core focus on people, innovation, and quality no...

CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing

KAWASAKI, Japan & SANTA ANA, Calif.--(BUSINESS WIRE)--Chitose Laboratory Corp., (CHITOSE), a leading company of the bioeconomy and provider of advanced cell line development services, and FUJIFILM Biosciences Inc., a global leader in the innovation and manufacture of cell culture solutions for the life science market, today announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production. CHITOSE’s expertise in cell line development usi...

FUJIFILM Biosciences Introduces BalanCD HEK293 Perfusion A Medium to Enable Gene Therapy Production

SANTA ANA, Calif.--(BUSINESS WIRE)--FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, today announced the commercial launch of BalanCD HEK293 Perfusion A. Designed to expand and augment the company’s portfolio of gene therapy application solutions, BalanCD HEK293 Perfusion A uses suspension HEK293 cells and perfusion technology to provide reliable, efficient, and scalable production of viral vectors for development of...
Back to Newsroom